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ABSTRACT
Should interferon alpha (IFN-α) be considered the
standard of care for the adjuvant therapy of high-risk
malignant melanoma? For 2003, it was estimated that
51,400 cases of invasive melanoma would be diagnosed.
The risk of recurrence after surgery is reported to be
approximately 60% for patients with thick primary
lesions (T4N0M0, American Joint Committee on
Cancer [AJCC] stage IIB) and 75% for patients with
regional nodal metastases (T1-4N1M0, AJCC stage III).
The observation that melanoma is susceptible to attack
by the host’s immune system has resulted in the testing
of a remarkably broad spectrum of immunotherapies in
the adjuvant setting. Many of these approaches failed to
demonstrate a significant clinical impact, until the use
of adjuvant IFN-α. Conflicting data from several large,
randomized clinical trials resulted in a rapid rise and
then decline in the use of IFN-α in the adjuvant setting.
This roller coaster has left many clinicians still hesitant
to strongly recommend it, and the use of adjuvant IFN-
α in high-risk melanoma remains controversial. This
manuscript reviews the leading arguments for and
against its routine use and addresses questions regard-
ing its role in the management of high-risk malignant
melanoma. The Oncologist 2003;8:451-458
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INTRODUCTION
Over the past several decades, the incidence of melanoma
has increased at a faster rate than that of any other solid tumor.
In the 1930s, the lifetime risk for a person living in the U.S.
to develop melanoma was 1 in 1,500. Currently, that risk is 1
in 74, and for 2003 it was estimated that 51,400 cases of inva-
sive melanoma would be diagnosed [1]. Early recognition and
excision of the primary tumor provide the best opportunity for
cure. While efforts to improve early diagnosis through educa-
tion have resulted in the increased detection of early-stage
melanoma, many patients still present with high-risk primary
melanomas. Patients with thick primary lesions (T4N0M0,
American Joint Committee on Cancer [AJCC] stage IIB) and
those with regional nodal metastases (T1-4N1M0, AJCC
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stage III) have a reported 5-year survival rate ranging from
30%-70%. This dismal prognosis is related to the high fail-
ure rates associated with surgical therapy in locally and
regionally advanced cases. The risk of recurrence after
surgery is reported to be approximately 60% for stage IIB
patients and 75% for stage III patients [2]. Compounding
this has been the lack of effective adjuvant therapy, partic-
ularly the limited efficacy of cytotoxic chemotherapeutic
agents against melanoma.
A beacon of hope in the treatment of melanoma has
long been the observation that melanoma is susceptible to
attack by the host’s immune system. This has resulted in the
testing of a remarkably broad spectrum of immunothera-
pies, including the use of nonspecific immunostimulants,
various approaches to vaccine therapies, and cytokine ther-
apy. Many of these approaches failed to demonstrate a sig-
nificant clinical impact, and the practitioner had been left
with few options in treating high-risk melanoma patients
with adjuvant therapy. One exception to this, however, has
been the use of adjuvant interferon alpha (IFN-α).
The interferons are cytokines with diverse immuno-
modulatory effects on tumor cells. Of the multiple subsets of
interferons, IFN-α has been shown to possess a reasonable
degree of activity against melanoma. While the precise mech-
anism of action remains poorly understood, there are multiple
antitumor effects of IFN-α. These include a direct antiprolif-
erative effect, the enhancement of natural killer cell activity,
and the upregulation of tumor antigens and/or HLA class I
and class II antigens [3]. Initial phase II clinical studies with
IFN-α in metastatic melanoma showed response rates in the
10%-20% range [4, 5]. These response rates, while encourag-
ing, were not significant enough to lead to its widespread use
in the treatment of metastatic melanoma. However, observa-
tions that patients with nonvisceral disease were more likely
to respond suggested that the use of IFN-α may demonstrate
a greater impact in patients with micrometastases [6].
This prompted multiple clinical trials exploring the use of
IFN-α as an adjuvant therapy for melanoma in patients at high
risk of recurrence. Several of these adjuvant trials had positive
results. In 1995, the Eastern Cooperative Oncology Group
(ECOG) trial E1684 demonstrated significantly longer
relapse-free survival (RFS) and overall survival rates with the
use of adjuvant high-dose IFN-α. Based on that study, the
U.S. Food and Drug Administration (FDA) approved the use
of IFN-α for the postsurgical adjuvant therapy of high-risk
melanoma. Suddenly this became the standard of care, and the
use of IFN-α was widely adopted in the community.
Unfortunately, the results of both early and subsequent trials
have not been as clear as had been hoped, and the adjuvant
use of interferon in the treatment of melanoma remains con-
troversial. This article summarizes the arguments in favor of
and against the routine use of adjuvant IFN-α for patients
with high-risk melanoma.
PROS: ARGUMENTS FOR ADJUVANT IFN-α
The Randomized Trials for High-Dose IFN-α2b Have Clearly
Demonstrated an Improved Disease-Free Survival, and the
Majority of Trials Have Demonstrated an Improved Overall
Survival
Trials involving adjuvant IFN-α have involved both
low-dose and high-dose regimens. The low-dose IFN-α
regimen consists of 2-3 mU administered 2-3 times per
week for periods of time ranging from 1 to 3 years. While
early results suggested that there may be some effectiveness
with the low-dose regimens [7, 8], reanalysis and additional
trials have demonstrated no benefit to survival [9, 10].
Increasing the IFN-α dose seems to provide an
improvement in outcome, as first suggested by Creagan et
al. and the North Central Cancer Treatment Group
(NCCTG) in their report of a randomized trial of patients at
intermediate and high risks of recurrence [11]. In that study,
patients were treated with 3 months of IFN-α2a 20 mU/m2
administered i.m. three times per week. There was a signif-
icantly greater disease-free survival rate for node-positive
patients and a trend toward improved overall survival in
that subset (47% versus 39% at 5 years), but this was not
statistically significant within this small study (262 patients
overall, 160 node positive).
When an even greater dose was used, a clear improve-
ment in survival was noted. Kirkwood et al. examined the use
of a very high dose of interferon in a randomized trial for the
ECOG, E1684 [12]. This regimen involved an induction
phase of IFN-α2b 20 mU/m2 i.v. 5 days a week for 4 weeks
followed by a maintenance phase of 10 mU/m2 s.c. 3 days a
week for the remainder of a year. That regimen was near the
maximally tolerated dose and was quite toxic. The results,
however, were notably positive. Patients randomized to the
treatment group had significantly better disease-free and
overall survival rates compared with the control group. IFN-
α2b therapy resulted in a median RFS time that was longer
by 9 months (1.72 years for IFN-α2b patients versus 0.98
years for observation patients) and produced a 42% greater 5-
year RFS rate (37% for IFN-α2b patients versus 26% for
observation patients). In addition, IFN-α2b therapy resulted
in a median survival time that was significantly greater by 1
year and produced a 24% better 5-year survival rate (46% for
IFN-α2b patients versus 37% for observation patients).
Based on those results, IFN-α2b was approved by the FDA
for the adjuvant treatment of high-risk melanoma.
Following the E1684 trial, an ECOG-coordinated inter-
group trial was initiated to provide much-needed verification
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of the overall benefit of adjuvant IFN-α and allow a more
precise appraisal of the benefit of therapy in the group of
patients with thick, node-negative melanomas. The E1690
trial compared high-dose IFN-α2b and a 2-year low-dose
IFN-α2b regimen with observation after complete resection
of all known disease [13]. Results of that trial confirmed the
disease-free survival advantage for high-dose IFN-α seen
in the E1684 trial but not the survival advantage. Advocates
of adjuvant interferon therapy point out that this discrep-
ancy is likely due to the result of differences in eligibility
criteria and, more importantly, the subsequent availability
of postrelapse IFN-α2b crossover therapy in the E1690 trial
compared with the E1684 trial.
A third trial, Intergroup E1694, compared 1 year of
high-dose IFN-α2b with 2 years of a vaccine called GMK,
containing the ganglioside GM2. Gangliosides are carbohy-
drate antigens found on the surface of melanoma cells as
well as normal cells of neural crest origin and tumor cells
of other types. A pilot randomized trial suggested a disease-
free survival benefit in patients who were treated with GM2
plus Calmette-Guerin bacilli (BCG) versus those treated
with BCG alone following resection of stage III disease
[14]. In May 2000, the independent Data Safety Monitoring
Committee of the E1694 trial concluded that the high-dose
interferon arm was associated with highly significant
greater RFS and overall survival rates and mandated that
the study be terminated early and the results disclosed [15].
Compared with the observation arms of the E1684 and
E1690 trials, there appeared to be no untoward effects of
the GMK vaccine on survival. Therefore, of the four major
randomized trials, all four demonstrated improvement in
RFS, and three of the four demonstrated improvements in
overall survival (although the NCCTG trial did not reach
statistical significance). Looked upon as a whole, these
results validate the benefit of high-dose interferon for the
adjuvant therapy of high-risk, resected melanoma.
The Cost of Treatment with High-Dose Interferon is
Comparable with Chemotherapy for Other Malignancies
In today’s world of limited health-care dollars, it is
imperative that new therapies be cost-efficient. The cost-
effectiveness of high-dose IFN-α2b for patients with high-
risk resected melanoma was assessed based on the results of
the original E1684 trial. The cost of 1 year of IFN-α2b treat-
ment was estimated to be just under $29,000 in that analy-
sis. The cost-effectiveness was found to be comparable with
other recognized medical therapies, ranging from $32,600-
$43,200 per year of life saved [16]. A cost-effectiveness
analysis of adjuvant interferon in Spain, also based on the
E1684 data, demonstrated that its use was within limits
established in health economics and was comparable with
other interventions in which the cost-effectiveness was
acceptable [17].
The Toxicities Associated with Treatment are Worthwhile
The toxicities associated with IFNα-2b are significant.
In the E1684 trial, treatment was reduced or discontinued in
over half the patients, and there were two treatment-related
deaths. However, the adjuvant use of IFNα-2b is supported
by the results of a quality-of-life-adjusted survival analysis
(Quality-Adjusted Time Without Symptoms and Toxicity,
Q-TWiST) [18]. Using the Q-TWiST methodology,
patients with stage III melanoma randomized to high-dose
interferon in the E1684 trial were found to have more time
without symptoms or toxicities than the observation group.
The treatment group had a mean of 8.9 months more time
without disease relapse and 7 months longer overall sur-
vival time compared with the observation group; they expe-
rienced an average of 5.8 months of severe
treatment-related toxicities. This supports the use of IFN-α
as adjuvant therapy. If the quality of life during the time
with toxicities is valued more highly than the quality of life
during the time after relapse, the group receiving interferon
had a significantly greater quality-of-life-adjusted time than
did the observation group.
There are No Other Effective Adjuvant Therapies
The need for adjuvant therapy in the treatment of
melanoma is dramatic. Patients with thick primary
melanomas (>4 mm) or melanoma metastatic to the
regional lymph nodes have relapse rates of 50%-90%. Once
distant metastases develop, median survival is only 6 to 9
months. Thus, the development of adjuvant systemic ther-
apy that can reduce the recurrence rate of melanoma has
been a critical area of investigation. However, to date, no
large randomized trial of adjuvant chemotherapy, radiation
therapy, or vaccine therapy has shown a benefit in high-risk
melanoma patients.
The use of chemotherapy for the adjuvant therapy of
high-risk melanoma has been ineffective. This is not surpris-
ing given the poor response rates associated with chemother-
apy against metastatic melanoma. Dacarbazine (DTIC) was
the first agent to show significant activity in melanoma, and
it remains the only chemotherapeutic drug approved on label
for the treatment of metastatic melanoma [19]. Combination
chemotherapy has demonstrated mildly improved response
rates, but has not resulted in a significantly greater survival
rate versus DTIC alone in stage IV melanoma. In the adju-
vant setting, chemotherapy has been a disappointment [20].
For example, a large, multicenter randomized trial performed
by the World Health Organization evaluated 761 patients
with Clark’s level III-V node-negative truncal melanomas or
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any melanoma with positive nodes [21]. Patients were ran-
domized to receive either DTIC alone, BCG alone, BCG plus
DTIC, or observation. After a median follow-up of 41
months, no difference in disease-free or overall survival was
detected for any group.
Melanoma vaccines hold the most promise in the adju-
vant setting, potentially able to improve disease-free and
overall survival rates with minimal toxicities. However, the
promise of melanoma vaccines has been hinted at for over
40 years without any established clinical benefit. To date,
no large, prospective randomized trial has demonstrated an
improvement in overall survival associated with vaccine
therapies. Many trials have shown that vaccines can effec-
tively generate a quantifiable specific immune response,
but it has not been clearly shown that such a response
results in long-term survival benefits. Many questions
regarding vaccines remain unanswered, and none are ready
for off-protocol use [22].
CONS: ARGUMENTS AGAINST THE USE OF
ADJUVANT IFN-α
The FDA Approved IFN-α Too Quickly
The E1684 trial, which established the adjuvant use of
IFN-α2b, is not without limitations. Patients were not strat-
ified by the number of positive lymph nodes, a recognized
prognostic factor. Therefore, it is possible that there may
have been an unrecognized imbalance between the treat-
ment and control groups that influenced the outcome.
However, the substantial relapse rate associated with high-
risk melanoma and the lack of effective adjuvant therapies
led to the rapid FDA approval of IFN-α. This occurred
despite multiple trials showing no overall survival benefit to
varying doses of interferon and the lack of a confirmatory
trial for high-dose interferon. In addition, the FDA approved
1 year of high-dose IFN-α2b as adjuvant therapy for stage
IIb as well as stage III disease, despite there not being
enough stage IIb patients in the trial to make a statistical
analysis of that subgroup.
Despite the benefit demonstrated in the E1684 trial, many
patients and physicians did not readily accept the treatment,
mostly due to the significant side effects and cost of treatment.
The disappointing results from the E1690 trial obviously led
to a substantial decline in the use of interferon in clinical prac-
tice. The E1694 trial revitalized its use, but this roller coaster
has left many clinicians still hesitant to strongly recommend
it. In addition, despite the enthusiasm and multiple large con-
trolled studies, there has been no demonstrable rationale of
the mechanisms of action of this biologic response modifier
[23]. Basic studies are still required to clarify the mechanism
of action to better define the role of this drug in the treatment
of melanoma. Having an FDA-approved adjuvant treatment
available, without clear answers as to the best use of it clini-
cally, precludes many patients from participating in clinical
trials necessary to provide those answers.
It is Unclear Which High-Risk Patients Would Most Benefit
From Adjuvant Therapy
When discussing the high-risk melanoma patient, we
typically refer to either the patient with a thick primary
melanoma or the patient with metastases to the regional
node. In the NCCTG trial, there was no effect demonstrated
in node-negative patients. Likewise, in the E1684 trial, the
beneficial effect was confined to node-positive patients.
Patients with thick primary melanomas who were node-
negative accounted for only a small subset (about 11% of
the 280 total patients) of the trial, and within that subset, the
treatment group actually fared worse. The small size of that
subset makes it impossible to determine whether there was
truly a difference in the response of node-positive and
node-negative patients to interferon treatment. The E1690
trial showed no benefit to the RFS rate in node-negative
patients, while the E1694 trial showed a significant benefit in
that population. Taken together, however, of the four major
trials, three demonstrated no survival advantage to adjuvant
interferon in patients with thick primary melanomas but no
lymph node involvement. This makes it much more difficult
to recommend the use of adjuvant IFN-α2b in that patient
population.
Even in node-positive patients, the data are not com-
pletely clear. The risk of relapse increases with the number
of lymph nodes containing metastatic disease [2]. The
E1684 trial was not stratified for the number of positive
nodes, but, retrospectively, the greatest RFS benefit
appeared to be for patients with one positive lymph node
[15]. Both the E1690 and E1694 trials were stratified for 0,
1, 2-3, and 4+ nodes. The E1690 trial showed that, when
stratified by the number of nodes, the RFS benefit was only
significant in patients who had 2-3 positive lymph nodes.
Kaplan-Meier estimates of RFS in the E1694 trial showed
no significant benefit in patients with 1, 2-3, or >4 involved
lymph nodes. This leaves open questions as to which popu-
lation of high-risk patients would benefit from high-dose
interferon. It is important to note that several of those stud-
ies were performed prior to sentinel lymph node technology
becoming standard of care. Whereas many of the patients in
those trials had grossly positive nodes or multiple lymph
nodes involved, today we see many patients with
micrometastases in the sentinel lymph node only. The role
of adjuvant interferon in that population is unknown, and is
presently being addressed by the ongoing Sunbelt
Melanoma Trial.
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There are Too Many Questions Among the Randomized Trials
Concerns about the E1684 trial, specifically the possi-
ble imbalance between the treatment and control groups,
were supposed to be addressed in the E1690 trial. As men-
tioned, however, while there was a greater disease-free sur-
vival for patients given high-dose IFN-α, the study failed to
demonstrate a greater overall survival for patients given
either high- or low-dose IFN-α. Advocates of interferon
therapy argue that the failure of the E1690 trial to validate
the E1684 trial was due to crossover therapy, the use of off-
protocol high-dose IFN-α by patients in the observation
arm after relapse. These crossover data have never been
adequately published and this must be considered an
unproven hypothesis. With so many differences between
the two trials, it is difficult to directly compare the results.
However, when a follow-up trial meant to verify early
results fails to do so, it is hard to dismiss those results and
recommend treatment regardless. Supporters of adjuvant
IFN-α state that a third trial, the E1694 trial, confirmed the
disease-free and overall survival benefits of high-dose IFN-
α2b demonstrated in the E1684 trial. However, that study
did not have an observation arm. Therefore, a deleterious
effect of the GMK vaccine cannot be ruled out. Such an
effect would lead to the appearance of a benefit for IFN-α
in that trial when none existed.
Even assuming that the GMK vaccine had no detrimen-
tal effect on survival, the E1694 trial is not a pure confir-
mation of the results of the E1684 trial. As described above,
the E1684 trial demonstrated the greatest RFS benefit of
high-dose IFN-α2b among patients presenting with one
positive lymph node. In the E1690 trial, the subset with the
greatest RFS benefit, and the only one reaching indepen-
dent statistical significance, was the group of patients with
2-3 positive nodes. Finally, the E1694 trial demonstrated
the greatest benefit, and again the only independently sta-
tistically significant benefit, in the node-negative subset.
One possible explanation is that the RFS benefit of IFN-
α2b may be stage independent, and the relative risk of
relapse may be reduced to a similar degree across sub-
groups [15]. However, the striking differences among the
three trials in regard to which patient population derived the
greatest benefit (if any) give pause to strongly recommend-
ing high-dose interferon to all high-risk melanoma patients.
The Toxicities are Too Great
The toxicities surrounding the use of IFN-α are not
inconsequential. In the E1684 trial, both treatment delays
and dosage reductions were required during therapy,
including 50% of patients during the induction period and
48% of patients during the maintenance phase. Grade 3 tox-
icities were seen in 67% of all treated patients at some time
in their therapy, while 9% had grade 4 toxicities. Serious
side effects included fatigue, flu-like symptoms (malaise,
fevers, chills, arthralgias), liver function abnormalities
(fatal hepatotoxicity has been observed in patients who
were not carefully monitored and appropriately dose-
reduced in the event of liver function test elevations), neu-
tropenia, nausea and vomiting, and psychiatric symptoms
including depression and suicide. Careful attention to
dose-reduction criteria and liberal use of i.v. fluids,
antiemetics, and antidepressants can moderate the side
effects. However, the successful administration of high-
dose IFN-α2b adjuvant therapy requires a committed team
including oncologists, nurses, pharmacists, social workers,
and psychiatrists/psychologists.
Despite the significant toxicities, proponents of IFN-α
point to the Q-TWiST analysis described above as support
for assuring patients that the significant toxicities of therapy
appear justified. However, that is the only study of quality
of life with adjuvant IFN-α, and there are several problems
[20]. First, the analysis was done retrospectively using the
collected data from the E1684 trial, without prospective
collection of quality-of-life data from participants in the
trial. The analysis assigned arbitrary relative values to time
with toxicity and time with relapse, rather than assessing
the actual quality-of-life valuations of the individual
patients in the trial. Also, the improvement in overall sur-
vival used in that analysis was not reproduced in the E1690
trial, but the Q-TWiST analysis was never updated. More
importantly, the Q-TWiST conclusion is based on the
assumption that the quality of life of a patient who has
symptoms but is disease-free is valued more highly than
that of a patient who has relapsed but has no symptoms. If
one assumes that the relative values are equal, then the
quality-of-life-adjusted time was not statistically signifi-
cantly greater for patients receiving interferon than for
those in the observation group. Patients certainly are averse
to the side effects of IFN-α; they regularly refuse the rec-
ommendation for treatment and seek alternatives in clinical
trials or chose to forego adjuvant therapy altogether.
Another important point to consider is that the studies
demonstrating the cost-effectiveness of interferon as adju-
vant therapy are based solely on the E1684 trial data. That
trial showed a dramatic benefit to the use of adjuvant inter-
feron in both disease-free and overall survival rates. In
addition, those analyses used projections of long-term sur-
vival, since data were only available for 5 years. Given the
improved survival of patients in the control arms in both
subsequent high-dose interferon trials and the lack of a
demonstrated benefit in the E1690 trial, those analyses may
not accurately reflect the economic cost-benefit ratios of
using adjuvant high-dose IFN-α2b.
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There are Other Less Toxic Immunotherapies Right Around
the Corner
Vaccine treatments for patients with high-risk primaries
or patients with regional lymph-node involvement remain a
promising area of clinical investigation, and may be the next
breakthrough in melanoma therapy. Vaccines offer the poten-
tial for improving disease-free and overall survival rates with
minimal toxicities. Two John Wayne Cancer Institute phase
III trials testing an allogeneic polyvalent irradiated whole-cell
allogeneic melanoma vaccine are currently under way.
Compared with historical controls, the phase II results with
this allogeneic vaccine showed significantly better survival
rates, and certainly supported phase III testing [24].
Furthermore, a great deal of immunologic correlative data (as
much or more than was available when IFN-α entered phase
III testing) supports the activity of this polyvalent vaccine [25,
26]. Another allogeneic melanoma vaccine, this one a whole-
cell lysate, has undergone phase III testing by the Southwest
Oncology Group (SWOG) in patients with intermediate-
thickness, node-negative melanoma (SWOG-9035). The
compelling rationale for choosing this vaccine was a low, but
definite, level of antitumor activity for the vaccine in
advanced disease. The results of the SWOG-9035 trial
revealed a trend toward better relapse-free survival in the vac-
cine arm; this reached statistical significance when all ran-
domized patients were considered [27]. Several other
approaches to vaccine therapy are presently in clinical trials.
To discover the potential benefits of this novel approach,
patients with high-risk melanoma should be encouraged to
participate in clinical vaccine trials. However, the use of IFN-
α outside of clinical trials decreases participation in these tri-
als, and any requirement to compare vaccines with IFN-α in
randomized trials (as was done in the E1694 trial) limits the
ability to determine the relative benefit of vaccine treatment.
CONCLUSION
The use of adjuvant IFN-α in high-risk melanoma
patients remains controversial and is likely to remain so until
additional clinical trial information becomes available. Is it
possible, however, to compare the relevant pro and con argu-
ments and come to some justifiable conclusions? Certainly
there seem to be some conclusions with which nearly all
melanoma physicians would agree. They are listed below.
• Regardless of one’s position on the relative benefit of
IFN-α adjuvant therapy, we can and must do better.
Clinical trials are urgently needed to address the fol-
lowing issues:
— Are there effective agents that can replace or add
to IFN-α in the adjuvant therapy of high-risk
melanoma?
— Can we decrease the toxicity of the current high-
dose regimen without losing efficacy, thereby
mitigating some of the contrary arguments to 
its use?
— Can we shorten the duration of the current high-
dose regimen without losing efficacy, thereby
mitigating some of the contrary arguments to 
its use?
— Can we do better in selecting which melanoma
patients are at highest risk for relapse, thus elim-
inating the need for adjuvant IFN-α in some
patients destined not to benefit from it?
• Regardless of one’s position on the relative benefit of
IFN-α adjuvant therapy for high-risk melanoma, vir-
tually all clinicians and patients agree that the toxici-
ties of therapy are too high for patients with
intermediate risks of recurrence, such as those with
lower risk primaries and pathologically negative sen-
tinel lymph nodes. Nonetheless, the risk of recurrence
in those patients is sufficiently great to justify adju-
vant therapy with low short- and long-term toxicities.
Clinical trials in intermediate-risk patients should
continue, including trials of less intense IFN-α regi-
mens and also phase II and phase III vaccine trials.
• Regardless of one’s position on the relative benefit of
IFN-α adjuvant therapy for high-risk melanoma,
some informed patients continue to feel that the toxi-
cities of therapy are too high, and they seek alterna-
tive therapies. Those patients should not be precluded
from participating in well-designed, controlled trials
that include a no-treatment control arm.
What then of the more contentious issue of the value of
IFN-α in the adjuvant setting for high-risk melanoma? How
do the authors of this treatise weigh the relative arguments
pro and con?
• Is high-dose IFN-α2b effective?
YES. Too many clinical trials demonstrate an
improvement in relapse-free survival to deny the fact
that high-dose IFN-α2b alters the natural history of
high-risk melanoma. If the E1694 trial is accepted as
a clinical trial that documents a significant impact of
high-dose IFN-α2b on overall survival, then it is
impossible not to conclude that adjuvant therapy with
high-dose IFN-α2b should be routinely offered to
healthy melanoma patients at high risk of relapse.
• Should the E1694 trial be accepted as supporting the
benefit of high-dose IFN-α on survival?
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YES. The likelihood that vaccination with a ganglio-
side antigen can result in a markedly greater risk of
early dissemination of and death from metastatic
melanoma is so far-fetched as to defy reasonable
belief. There is credible evidence that anti-GM2 anti-
bodies, either spontaneous or vaccine induced, are
protective against melanoma relapse, including evi-
dence from the E1694 trial itself, but no credible evi-
dence of antibodies inducing an exacerbation of
melanoma or any human cancer. It is noteworthy that
the strongest public proponents of the “killer vaccine”
theory offer no such criticisms of the previous clini-
cal data in support of GM2 vaccination, and indeed,
in many cases, continue to test either the GMK vac-
cine itself or other vaccines containing GM2 in clini-
cal trials in melanoma patients.
• Are there any subsets of high-risk melanoma patients
that do not benefit from high-dose IFN-α?
NO. The most plausible explanation of the available
data is that the absolute efficacy of IFN-α is consis-
tent across all subsets of high-risk patients: thick
node-negative, microscopic node-positive, and
macroscopic node-positive at initial presentation and
recurrence. It also seems highly reasonable to
extrapolate the available clinical trial data to patients
at similar or even higher risks of relapse, such as
patients with intermediate-thickness, ulcerated
melanomas and negative sentinel nodes and patients
with completely resected metastatic melanoma. It
must be noted, however, that the subset of high-risk
patients with the least clinical trial data is the group
of patients that is now most commonly treated with
adjuvant IFN-α, namely, those patients with a sin-
gle, microscopically positive lymph node found on
sentinel node biopsy. More data on the results of
untreated and IFN-α-treated patients in this sub-
group are sorely needed and would enhance the
acceptability of adjuvant treatment by physicians
and patients alike.
• Is observation a reasonable alternative for informed,
high-risk patients who choose not to accept high-dose
IFN-α therapy?
ABSOLUTELY. The authors find the available evi-
dence in favor of IFN-α compelling, but not to the
point where informed patients could not make a rea-
sonable decision to forego treatment or seek alternate
or investigational therapy. Moreover, the crossover
effect observed in the E1690 trial suggests that an
untreated high-risk patient who subsequently presents
with a resectable recurrence might still derive benefit
from adjuvant IFN-α, and this should be explained
and offered to patients who choose to forego initial
IFN-α adjuvant therapy. It must be noted, however,
that most contemporary high-risk melanoma patients
do not develop resectable recurrences. The wide-
spread adoption of sentinel node biopsy for node stag-
ing has resulted in fewer recurrences in regional node
basins than the previous practice of clinical staging of
nodes. Most contemporary patients with pathologic
stage II and stage III disease who develop disease
recurrence will not have an option for surgical sal-
vage and subsequent adjuvant IFN-α therapy.
It took nearly 40 years of intensive clinical investiga-
tion to develop the first adjuvant therapy regimen with a
reproducible and sustained impact on the natural history of
high-risk melanoma after surgery. Even in the year 2001,
almost all patients who developed nonresectable stage IV
melanoma died of their disease. This is a sobering thought,
and one that deserves careful consideration in every conver-
sation with melanoma patients regarding adjuvant therapy.
As we continue to investigate ways to do better, the small
but significant gains made to date should not be discarded
lightly. Balancing the pros and cons, adjuvant therapy with
high-dose IFN-α2b is an important part of the treatment of
melanoma. Proponents and opponents of IFN-α should
strive to agree on one more thing: let’s make the need for
adjuvant therapy obsolete by a worldwide commitment to
earlier detection and primary prevention!
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